Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab

Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study

(2020) Alessio Cortellini et al.   Scientific Reports

Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma

(2020) Nalee Kim et al.   JOURNAL OF HEPATOLOGY

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report

(2019) Alessio Cortellini et al.   Thoracic Cancer

Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

(2019) Christine Ménétrier-Caux et al.   Journal for ImmunoTherapy of Cancer

2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

(2019) KLCA Korean Liver Cancer Association et al.   Gut and Liver

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma

(2019) Changhoon Choi et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer

(2019) Yeona Cho et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition

(2019) Jared M. Newton et al.   Journal for ImmunoTherapy of Cancer

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma

(2019) Jeong Il Yu et al.   Cancer Medicine

Skeletal muscle as potential central link between sarcopenia and immune senescence

(2019) Christopher Nelke et al.   EBioMedicine

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy

(2019) Mehmet Asim Bilen et al.   ONCOLOGIST

Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment

(2018) Hirotake Tsukamoto et al.   CANCER RESEARCH

A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors

(2018) Bhanu Prasad Venkatesulu et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

(2018) Mariaelena Capone et al.   Journal for ImmunoTherapy of Cancer

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

(2018) Won Jin Ho et al.   Journal for ImmunoTherapy of Cancer

Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients

(2017) Valentine Heidelberger et al.   INVESTIGATIONAL NEW DRUGS

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

(2017) Stephen J. Bagley et al.   LUNG CANCER

Radiotherapy and immunotherapy: a beneficial liaison?

(2017) Ralph R. Weichselbaum et al.   Nature Reviews Clinical Oncology

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors

(2017) Adam Diehl et al.   Oncotarget

Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer

(2017) Elizabeth M. Cespedes Feliciano et al.   JAMA Oncology

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity

(2016) Thomas R. Flint et al.   Cell Metabolism

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy

(2016) Laurent Dercle et al.   EUROPEAN JOURNAL OF CANCER

Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria

(2016) Hiroki Nishikawa et al.   HEPATOLOGY RESEARCH

Excess TGF-β mediates muscle weakness associated with bone metastases in mice

(2015) David L Waning et al.   NATURE MEDICINE

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

(2014) Arnoud J. Templeton et al.   JNCI-Journal of the National Cancer Institute

Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies

(2010) Shontelle Dodson et al.   Annual Review of Medicine

Systemic effects of local radiotherapy

(2009) Silvia C Formenti et al.   LANCET ONCOLOGY